Top 19 Parkinson's disease startups in USA
Dec 17, 2025
|
Like
28
1
Funding: $11.5M
AiM Medical Robotics is developing portable, MRI-compatible surgical robot that can be useed in the MRI room and operating room. The company's goal is to improve outcomes for patients undergoing neurosurgery for functional brain disorders (Parkinson's disease, epilepsy, etc.) and brain cancer. It also can save hospitals money by eliminating errors and reducing procedure time. AiM's robotic platform can integrate into existing workflow and provide surgeons with real-time intraoperative MRI visualization combined with robotic control to ensure precise placement of neurostimulation electrodes, biopsies, tumor ablation and targeted intracranial delivery of therapeutic drugs. The system leverages AI to provide surgeons with predictive information in real time.
AiM Medical Robotics is developing portable, MRI-compatible surgical robot that can be useed in the MRI room and operating room. The company's goal is to improve outcomes for patients undergoing neurosurgery for functional brain disorders (Parkinson's disease, epilepsy, etc.) and brain cancer. It also can save hospitals money by eliminating errors and reducing procedure time. AiM's robotic platform can integrate into existing workflow and provide surgeons with real-time intraoperative MRI visualization combined with robotic control to ensure precise placement of neurostimulation electrodes, biopsies, tumor ablation and targeted intracranial delivery of therapeutic drugs. The system leverages AI to provide surgeons with predictive information in real time.
2
Funding: $1.1B
Neurodegenerative diseases are one of the largest medical challenges of our time. Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development.
Neurodegenerative diseases are one of the largest medical challenges of our time. Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development.
3
Funding: $614.6M
Neumora Therapeutics develops precision therapies for treatment of brain diseases. Its uses the propriety platform Precision Toolbox, which includes a suite of translational, medical and computational tools for information discovery, capable of applying precision medicine approaches. Its therapeutic portfolio includes seven programs for the treatment of neuropsychiatric disorders and neurodegenerative diseases (major depressive disorder, Alzheimer's disease, schizophrenia, and Parkinson's disease). Neumora's lead program, navacaprant, is a novel, highly selective kappa opioid receptor (KOR) antagonist nearing the end of development as a reliable monotherapy for the treatment of MDD. Navacaprant is an investigational, once-daily oral medication designed to modulate dopamine and reward signaling pathways, which play a critical role in the regulation of mood, cognition, reward and behavior.
Neumora Therapeutics develops precision therapies for treatment of brain diseases. Its uses the propriety platform Precision Toolbox, which includes a suite of translational, medical and computational tools for information discovery, capable of applying precision medicine approaches. Its therapeutic portfolio includes seven programs for the treatment of neuropsychiatric disorders and neurodegenerative diseases (major depressive disorder, Alzheimer's disease, schizophrenia, and Parkinson's disease). Neumora's lead program, navacaprant, is a novel, highly selective kappa opioid receptor (KOR) antagonist nearing the end of development as a reliable monotherapy for the treatment of MDD. Navacaprant is an investigational, once-daily oral medication designed to modulate dopamine and reward signaling pathways, which play a critical role in the regulation of mood, cognition, reward and behavior.
4
Funding: $374M
Voyager Therapeutics is a clinical stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS). Gene therapy has the potential to transform the treatment of CNS and other diseases by providing a one-time therapy that dramatically improves patients' lives.
Voyager Therapeutics is a clinical stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS). Gene therapy has the potential to transform the treatment of CNS and other diseases by providing a one-time therapy that dramatically improves patients' lives.
5
Funding: $310M
Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease.
Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease.
6
Funding: $272M
Aspen Neuroscience is a private biotechnology company that uses innovative genomic approaches combined with stem cell biology.
Aspen Neuroscience is a private biotechnology company that uses innovative genomic approaches combined with stem cell biology.
7
Funding: $260M
Neurocrine Biosciences engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases.
Neurocrine Biosciences engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases.
8
Funding: $248.3M
Cala Health is a medical technology company pioneering a new class of electrical medicine called neuroperipheral therapy. Neuroperipheral therapy has the potential to address chronic disease by externally stimulating peripheral nerves with body-worn electronics. Cala Health is bringing together experts in neuroscience, consumer electronics, and medical devices to develop accessible therapies that treat chronic disease non-invasively.
Cala Health is a medical technology company pioneering a new class of electrical medicine called neuroperipheral therapy. Neuroperipheral therapy has the potential to address chronic disease by externally stimulating peripheral nerves with body-worn electronics. Cala Health is bringing together experts in neuroscience, consumer electronics, and medical devices to develop accessible therapies that treat chronic disease non-invasively.
9
Funding: $181.2M
Skyhawk develops small molecule therapeutics that modulate RNA expression for treatment of cancer, neurological diseases and rare diseases. The company's flagship RNA-targeting drug for Huntington's disease is currently in Phase III clinical trials. Skyhawk's platform consists of: SKYSTAR - system for identifying priority RNA targets, SKYLIBRARY - library of compounds for RNA targets, SKYSEQ - multiplex screening system that simultaneously tests dozens of important targets across various RNA motifs to identify compounds selective for a specific disease target and SKYAI - machine learning model that integrates data from SKYSTAR, medicinal chemistry, animal studies, toxicology studies and clinical programs to develop the next generation of novel RNA splicing modulators.
Skyhawk develops small molecule therapeutics that modulate RNA expression for treatment of cancer, neurological diseases and rare diseases. The company's flagship RNA-targeting drug for Huntington's disease is currently in Phase III clinical trials. Skyhawk's platform consists of: SKYSTAR - system for identifying priority RNA targets, SKYLIBRARY - library of compounds for RNA targets, SKYSEQ - multiplex screening system that simultaneously tests dozens of important targets across various RNA motifs to identify compounds selective for a specific disease target and SKYAI - machine learning model that integrates data from SKYSTAR, medicinal chemistry, animal studies, toxicology studies and clinical programs to develop the next generation of novel RNA splicing modulators.
10
Funding: $172M
vTv Therapeutics, a pharmaceutical company, focuses on the discovery and development of human therapeutics to fill unmet medical needs. Its mission is to utilize its innovative technology to rapidly translate the functional modulation of human proteins into safe and effective medicines.
vTv Therapeutics, a pharmaceutical company, focuses on the discovery and development of human therapeutics to fill unmet medical needs. Its mission is to utilize its innovative technology to rapidly translate the functional modulation of human proteins into safe and effective medicines.
11
Funding: $134.1M
We use genomic data to find better drugs, faster. We find new cures for brain diseases 1000X more cheaply and quickly using our proven network algorithms.
We use genomic data to find better drugs, faster. We find new cures for brain diseases 1000X more cheaply and quickly using our proven network algorithms.
12
Funding: $130.9M
Vertero Therapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and Central Nervous System to develop a new class of therapeutics to improve the quality of life for people with CNS diseases and disorders
Vertero Therapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and Central Nervous System to develop a new class of therapeutics to improve the quality of life for people with CNS diseases and disorders
13
Funding: $129M
Prevail Therapeutics is a biotechnology company focused on developing novel gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases.
Prevail Therapeutics is a biotechnology company focused on developing novel gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases.
14
Funding: $36M
Neuraly is a Johns Hopkins School of Medicine spinoff biotech company and aims to introduce the first, disease-modifying agent for neurodegenerative disorders and aging.
Neuraly is a Johns Hopkins School of Medicine spinoff biotech company and aims to introduce the first, disease-modifying agent for neurodegenerative disorders and aging.
15
Funding: $29M
Appello Pharmaceuticals is focused on advancing novel positive allosteric modulators of mGlu4 for the treatment of Parkinson’s disease.
Appello Pharmaceuticals is focused on advancing novel positive allosteric modulators of mGlu4 for the treatment of Parkinson’s disease.
16
Funding: $12.5M
OccamzRazor uses machine learning to find and develop curative treatments for Parkinson’s.
OccamzRazor uses machine learning to find and develop curative treatments for Parkinson’s.
17
Funding: $4.3M
De Oro Devices is a device that re-establishing the connection between the brain and the body.
De Oro Devices is a device that re-establishing the connection between the brain and the body.
18
Funding: $375K
Melior Pharmaceuticals is a clinical stage pharmaceutical company developing treatment for metabolic disease and skin disorders.
Melior Pharmaceuticals is a clinical stage pharmaceutical company developing treatment for metabolic disease and skin disorders.
19
VistaraBio is applying their proteostasis technologies for target identification in Parkinson's and other neurodegenerative diseases.
★
See also:
